In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer
Stéphanie Schrambach, Marc Ardizzone, Vincent Leymarie et al. · 2007
Read In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer by Stéphanie Schrambach, Marc Ardizzone, Vincent Leymarie et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000518.txt.
Introduction
Stéphanie Schrambach and colleagues mapped where two immune alarm proteins appear in the body, in a 2007 PLOS ONE paper. The proteins, MICA and MICB, appear on stressed or infected cells and flag them for immune attack. The team described their in vivo expression pattern and its relevance to auto-immunity and cancer.
Where a flag is normally raised decides where mistaken attacks can happen. If healthy tissues display MICA or MICB, the immune system may target them, feeding autoimmune disease; tumors may raise or shed them to escape. An expression map is the reference that such disease studies need before they can claim anything is abnormal.
Catalog record
| CREATOR | Stéphanie Schrambach, Marc Ardizzone, Vincent Leymarie et al. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000518
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer Authors: Stéphanie Schrambach, Marc Ardizzone, Vincent Leymarie, Jean Sibilia, Seiamak Bahram Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000518 ABSTRACT Non-conventional MHC class I MIC molecules interact not with the TCR, but with NKG2D, a C-type lectin activatory receptor present on most NK, γδ and CD8 + αβ T cells. While this interaction is critical in triggering/calibrating the cytotoxic activity of these cells, the actual extent of its in vivo involvement, in man, in infection, cancer or autoimmunity, needs further assessment. The latter has gained momentum along with the reported expansion of peripheral CD4 + CD28 − NKG2D + T cells in rheumatoid arthritis (RA). We first initiated to extend this report to a larger cohort of not only RA patients, but also those affected by systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). In RA and SS, this initial observation was further tested in target tissues: the joint and the salivary glands, respectively. In conclusion and despite occasional and indiscriminate expansion of the previously incriminated T cell subpopulation, no correlation could be observed between the CD4 + CD28 − NKG2D + and auto-immunity. Moreover, in situ , the presence of NKG2D matched that of CD8 + , but not that of CD4 + T cells. In parallel, a total body tissue scan of both MICA and MICB transcription clearly shows that despite original presumptions, and with the exception of the central nervous system, both genes are widely transcribed and therefore possibly translated and membrane-bound. Extending this analysis to a number of human tumors did not reveal a coherent pattern of expression vs. normal tissues. Collectively these data question previous assumptions, correlating a tissue-specific expression/induction of MIC in relevance to auto-immune or tumor processes. INTRODUCTION Cytotoxic CD8 + and helper CD4 + αβ T cells recognize conventional peptide-loaded Major Histocompatibility Complex (MHC) class I and II molecules respectively [1] . Whilst the former interaction leads to the elimination of the virally infected or the tumorized target cells, the latter, helps amplify/regulate primarily the humoral immune response against exo or auto-antigens [2] , [3] . Although this textbook definition of the adaptive immune response is clear, real life functional/dysfunctional implications of these interactions, in conjunction with the second, innate, actors of the immunity, is far from being simple. This is perhaps best exemplified in auto-immune reactions, where depending on the disease, the species (human or mouse in essence) and the experimental model, different components of the immune system have been sequentially put to the forefront, leading to the logical assumption that virtually all actors of the immune system are involved either in triggering and/or perpetuation of the disease [4] – [6] . Unlike the above mentioned conventional MHC-I molecules, MIC molecules [7] , [8] do not interact with the TCR per se but do so with NKG2D, a C-type lectin activatory receptor expressed on NK, γδ and CD8 + αβ T cells [9] , [10] . This interaction has been shown to over-ride the inhibitory signal provided by Killer Inhibitory Receptors (KIR) and/or CD94/NKG2A/B molecules which sense the presence of respectively HLA-ABC and -E on target cells. While on T cells, NKG2D functions as a co-stimulatory molecule [11] , it may activate NK cells as well as IL-15-activated intraepithelial T lymphocytes in a TCR independent fashion [12] . MIC-NKG2D engagement is believed to be consequently critical in eliminating infected cells and/or tumours [13] , [14] . Whether this interaction is also relevant in autoimmunity is a matter of more recent emphasis [15] . Rheumatoid arthritis (RA) is an archetypical auto-immune disease and as such resumes our present knowledge and challenges regarding autoimmunity [16] . A vast body of work has yielded to numerous hypotheses regarding the initiation and perpetuation of the disease. Throughout time, T cells or B cells have been recognized as the primary actors of the disease. The putative tissue-specific or systemic auto-antigen(s) in man remains elusive, in contrast to several natural or transgenic/gene targeted animal models where several self antigens have been recognized to able to initiate the disease [17] . One of the recent putative actors in RA pathogenesis has been forwarded as a discrete population of CD4 + T cells which lack the co-stimulatory molecule CD28 and have been reported to be expanded in RA [18] , [19] . More recent investigations reported that these T cells express, instead of CD28, the above described NKG2D [15] . The following work was initiated on this assumption and aimed to first replicate these initial data in a larger, better defined, cohort of RA patients. It was further extended to two other auto-immune diseases: systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). In RA and SS afflicted patients it was also possible to probe MIC expression level in target tissues, both at the messenger RNA and the protein level. Moreover in peripheral blood besides measuring the presence of CD4 + NKG2D + cells per se, we also set to analyze the TCR β repertoire of these cells in certain individuals (cf. infra ). Finally, and for the first time, a comprehensive organ/tissue scan allowed to uncover the fact that in contrast to what was initially assumed and has since entered textbooks [20] , and with the exception of the central nervous system, MICA and MICB were transcribed in virtually every tissue/organ examined. The further extension of this analysis to tumorized samples helped give a better grasp of MIC transcription in both health and disease. MATERIALS AND METHODS 25 healthy volunteers as well as 75 patients suffering from RA (n = 35; 1988 American College of Rheumatology criteria) [21] , SLE (n = 15; 1997 revised American College of Rheumatology criteria) [22] and SS (n = 25; 2002 American and European criteria) [23] were included in this study ( Table 1 ). All samples were obtained from volunteers attending the Rheumatology clinic of Strasbourg University Hospitals and were collected during routine clinical (diagnostic/prognostic/therapeutic) procedures prescribed by one of the co-authors, Dr. J. Sibilia. Written informed consent was obtained from each individual in agreement with the Helsinki Declaration and French legislation, under which no approval by an ethical committee was required in this case. All patients and controls were unrelated. DAS (Disease Activity Score) 28 for RA, SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) for SLE and mean AVS (AVS: Analogic Visual Scale) of subjective sicca syndrome, asthenia and pain for SS. Abbreviations: NSAID: Non-Steroidal Anti-Inflammatory Drugs; SMARD: Symptom Modifying Anti-Rheumatic Drugs; DCART: Disease Controlling Anti-Rheumatic Therapy; ANA: antinuclear antibody (indirect immunofluorescence on Hep2 cells), ENA: extractable nuclear antigens; dsDNA: double-stranded DNA, RF: Rheumatoid Factor, CCP: cyclic citrullinated peptide. TABLE: Characteristics of patients and healthy controls. Controls RA SLE SS Individuals (men/women) 25 (3/22) 35 (5/30) 15 (3/12) 25 (1/24) Mean age 37.5 (25–58) 49.7 (30–77) 38 (16–70) 56.5 (40–80) Disease duration (years) – 6.8 (1–25) 6.6 (3–16) 11.6 (2–42) Disease activity * – 4.7 (1.8–7.4) 0.5 (0–5) 64.6 (25–96.6) No treatment – 5 (14%) 3 (20%) 15 (60%) NSAID ** – 8 (23%) 0 0 Corticosteroids – 12 (40%) 6 (20%) 3 (12%) SMARD – 7 (20%) 6 (40%) 4 (16%) DCART – 13 (37%) 6 (40%)